Aged versus fresh autologous platelet transfusion in a two‐hit healthy volunteer model of transfusion‐related acute lung injury

Background Transfusion‐related acute lung injury (TRALI) is a severe complication of blood transfusion that is thought of as a two‐hit event: first the underlying patient condition (e.g., sepsis), and then the transfusion. Transfusion factors include human leukocyte antigen antibodies or biologic re...

Full description

Saved in:
Bibliographic Details
Published in:Transfusion (Philadelphia, Pa.) Pa.), 2022-12, Vol.62 (12), p.2490-2501
Main Authors: Baarle, Floor L. F., Bruin, Sanne, Bulle, Esther B., Mourik, Niels, Lim, Endry H. T., Tuip‐de Boer, Anita M., Bongers, Annabel, Wissel, Marit B., Bruggen, Robin, Korte, Dirk, Vermeulen, Christie, Tan, Khik Wie, Jonkers, René E., Bonta, Peter I., Lutter, René, Dekker, Tamara, Dierdorp, Barbara S., Peters, Anna L., Biemond, Bart J., Vlaar, Alexander P. J.
Format: Article
Language:English
Subjects:
Antibodies
Antigens
autologous blood transfusion
Bioaccumulation
Blood platelets
Blood transfusion
bronchoalveolar lavage
Bronchus
Chest
Endotoxemia
Histocompatibility antigen HLA
Humans
Inflammation
Interleukin 6
Lavage
Leukocytes
Leukocytes (neutrophilic)
Lipopolysaccharides
Lungs
Male
Peroxidase
platelet activation
platelet transfusion
Platelet Transfusion - adverse effects
Platelets
Risk management
Sepsis
Spirometry
Transfusion
Transfusion Complications
Transfusion-Related Acute Lung Injury - etiology
transfusion‐related acute lung injury
Tumor necrosis factor-α
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Transfusion‐related acute lung injury (TRALI) is a severe complication of blood transfusion that is thought of as a two‐hit event: first the underlying patient condition (e.g., sepsis), and then the transfusion. Transfusion factors include human leukocyte antigen antibodies or biologic response modifiers (BRMs) accumulating during storage. Preclinical studies show an increased TRALI risk with longer stored platelets, clinical studies are conflicting. We aim to discover whether longer platelet concentrate (PC) storage time increases TRALI risk in a controlled human experiment. Study Design and Methods In a randomized controlled trial, 18 healthy male volunteers received a first hit of experimental endotoxemia (2 ng/kg lipopolysaccharide), and a second hit of fresh (2‐day old) or aged (7‐day old) autologous PC, or physiological saline. After 6 h, changes in TRALI pathways were determined using spirometry, chest X‐ray, and bronchoalveolar lavage (BAL). Results All subjects reacted adequately to lipopolysaccharide infusion and satisfied SIRS criteria (increased pulse [>90/min] and temperature [>38°C]). There were no differences between the saline, fresh, and aged PC groups in BAL‐fluid protein (95 ± 33 μg/ml; 83 ± 21 μg/ml and 104 ± 29 μg/ml, respectively) and relative neutrophil count (1.5 ± 0.5%; 1.9 ± 0.8% and 1.3 ± 0.8%, respectively), nor in inflammatory BAL‐fluid BRMs (Interleukin‐6, CXCL8, TNFα , and myeloperoxidase), clinical respiratory parameters, and spirometry results. All chest X‐rays were normal. Conclusions In a human endotoxemia model of autologous platelet transfusion, with an adequate first hit and platelet storage lesion, transfusion of 7‐day‐old PC does not increase pulmonary inflammation compared with 2‐day‐old PC.
ISSN:0041-1132
1537-2995
DOI:10.1111/trf.17157